UY31137A1 - Derivados de quinazolina como inhibidores de la pi3 quinasa - Google Patents
Derivados de quinazolina como inhibidores de la pi3 quinasaInfo
- Publication number
- UY31137A1 UY31137A1 UY31137A UY31137A UY31137A1 UY 31137 A1 UY31137 A1 UY 31137A1 UY 31137 A UY31137 A UY 31137A UY 31137 A UY31137 A UY 31137A UY 31137 A1 UY31137 A1 UY 31137A1
- Authority
- UY
- Uruguay
- Prior art keywords
- diseases
- quinazoline
- derivatives
- invented
- quinasa
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Abstract
Se ha inventado un método para inhibir la actividad/función de quinasas PI3 usando derivados de quinazolina. También se ha inventado un método para tratar una o más patologías seleccionadas entre: trastornos autoinmunes, enfermedades inflamatorias, enfermedades cardiovasculares, enfermedades neurodegenerativas, alergia, asma, pancreatitis, fallo multiorgánico, enfermedades renales, agregación plaquetaria, cáncer, motilidad de los espermatozoides, rechazo de trasplantes, rechazo de injertos y lesiones pulmonares, mediante la administración de derivados de quinazolina.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US94389907P | 2007-06-14 | 2007-06-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY31137A1 true UY31137A1 (es) | 2009-01-05 |
Family
ID=40156899
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY31137A UY31137A1 (es) | 2007-06-14 | 2008-06-10 | Derivados de quinazolina como inhibidores de la pi3 quinasa |
Country Status (9)
Country | Link |
---|---|
US (2) | US20090018131A1 (es) |
EP (1) | EP2167092A4 (es) |
JP (1) | JP2010532320A (es) |
AR (1) | AR066978A1 (es) |
CL (1) | CL2008001743A1 (es) |
PE (1) | PE20090835A1 (es) |
TW (1) | TW200918068A (es) |
UY (1) | UY31137A1 (es) |
WO (1) | WO2008157191A2 (es) |
Families Citing this family (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UY31137A1 (es) * | 2007-06-14 | 2009-01-05 | Smithkline Beecham Corp | Derivados de quinazolina como inhibidores de la pi3 quinasa |
EP2183232B1 (en) | 2007-08-02 | 2013-03-06 | Amgen, Inc | Pi3 kinase modulators and methods of use |
EP2211615A4 (en) * | 2007-10-22 | 2010-10-13 | Glaxosmithkline Llc | PYRIDOSULFONAMIDE DERIVATIVES AS PI3 KINASE INHIBITORS |
CA2710194C (en) | 2007-12-19 | 2014-04-22 | Amgen Inc. | Inhibitors of p13 kinase |
CA2725014C (en) | 2008-05-30 | 2014-06-17 | Amgen Inc. | Inhibitors of pi3 kinase |
EP2370424A1 (en) | 2008-11-10 | 2011-10-05 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
RU2604066C2 (ru) | 2008-12-19 | 2016-12-10 | Вертекс Фармасьютикалз Инкорпорейтед | Производные пиразина, используемые в качестве ингибиторов киназы atr |
AU2010213014B2 (en) * | 2009-02-12 | 2016-02-25 | Merck Serono S.A. | 2-morpholino-pyrido[3,2-d]pyrimidines |
MX2011012198A (es) | 2009-05-15 | 2011-12-08 | Novartis Ag | Aril-piridinas como inhibidoras de sintasa de aldosterona. |
US9630956B2 (en) | 2010-05-12 | 2017-04-25 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US9062008B2 (en) | 2010-05-12 | 2015-06-23 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
JP2013526539A (ja) | 2010-05-12 | 2013-06-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | Atrキナーゼ阻害剤として有用なピラジン |
JP2013526538A (ja) | 2010-05-12 | 2013-06-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | Atrキナーゼ阻害剤として有用な化合物 |
US9334244B2 (en) | 2010-05-12 | 2016-05-10 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
MX2012013082A (es) | 2010-05-12 | 2013-05-09 | Vertex Pharma | Derivados de 2-aminopiridina utiles como iinhibidores de cinasa atr. |
EP2585468A1 (en) | 2010-06-23 | 2013-05-01 | Vertex Pharmaceuticals Incorporated | Pyrrolo- pyrazine derivatives useful as inhibitors of atr kinase |
DE102010049595A1 (de) | 2010-10-26 | 2012-04-26 | Merck Patent Gmbh | Chinazolinderivate |
WO2012125668A1 (en) * | 2011-03-17 | 2012-09-20 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF |
AU2012240030A1 (en) | 2011-04-05 | 2013-10-24 | Vertex Pharmaceuticals Incorporated | Aminopyrazine compounds useful as inhibitors of TRA kinase |
JP2014517079A (ja) | 2011-06-22 | 2014-07-17 | バーテックス ファーマシューティカルズ インコーポレイテッド | Atrキナーゼ阻害剤として有用な化合物 |
EP2723747A1 (en) | 2011-06-22 | 2014-04-30 | Vertex Pharmaceuticals Inc. | Compounds useful as inhibitors of atr kinase |
US8822469B2 (en) | 2011-06-22 | 2014-09-02 | Vertex Pharmaceuticals Incorporated | Pyrrolo[2,3-B]pyrazines useful as inhibitors of ATR kinase |
EP2751088B1 (en) | 2011-09-30 | 2016-04-13 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
SG11201401093WA (en) | 2011-09-30 | 2014-04-28 | Vertex Pharma | Processes for making compounds useful as inhibitors of atr kinase |
CN103957917A (zh) | 2011-09-30 | 2014-07-30 | 沃泰克斯药物股份有限公司 | 用atr抑制剂治疗胰腺癌和非小细胞肺癌 |
EP2751099B1 (en) | 2011-09-30 | 2017-06-14 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
WO2013049720A1 (en) | 2011-09-30 | 2013-04-04 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
EP2768813A1 (en) * | 2011-10-21 | 2014-08-27 | Novartis AG | Quinazoline derivatives as pi3k modulators |
EP2776429A1 (en) | 2011-11-09 | 2014-09-17 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
WO2013071088A1 (en) | 2011-11-09 | 2013-05-16 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
WO2013071085A1 (en) | 2011-11-09 | 2013-05-16 | Vertex Pharmaceuticals Incorporated | Pyrazine compounds useful as inhibitors of atr kinase |
US8841337B2 (en) | 2011-11-09 | 2014-09-23 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
WO2013071093A1 (en) | 2011-11-09 | 2013-05-16 | Vertex Pharmaceuticals Incorporated | Pyrazine compounds useful as inhibitors of atr kinase |
CA2857302C (en) * | 2011-12-15 | 2020-08-25 | Novartis Ag | Use of inhibitors of the activity or function of pi3k |
AU2013218148A1 (en) | 2012-02-06 | 2014-07-24 | Glaxosmithkline Intellectual Property (No. 2) Limited | PI3K inhibitors for treating fibrotic diseases |
BR112014018122A8 (pt) * | 2012-02-06 | 2017-07-11 | Glaxosmithkline Ip No 2 Ltd | Composto, uso de um composto, e, método para tratar tosse |
RS56673B1 (sr) | 2012-04-05 | 2018-03-30 | Vertex Pharma | Jedinjenja korisna kao inhibitori atr kinaze i kombinovane terapije koje ih koriste |
CN102746241B (zh) * | 2012-07-02 | 2014-11-05 | 西安交通大学 | 2,3,5-三取代苯甲酰胺类化合物及其制备方法和用途 |
DK2904406T3 (en) | 2012-10-04 | 2018-06-18 | Vertex Pharma | METHOD OF DETERMINING THE ATR INHIBITION, INCREASED DNA DAMAGE |
MX2015004327A (es) | 2012-10-16 | 2015-06-10 | Almirall Sa | Derivados de pirrolotriazinona como inhibidores de pi3k. |
EP2909202A1 (en) | 2012-10-16 | 2015-08-26 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
SI3808749T1 (sl) | 2012-12-07 | 2023-07-31 | Vertex Pharmaceuticals Incorporated | Pirazolo(1,5-A)pirimidini za uporabo kot zaviralci ATR kinaze pri zdravljenju rakavih bolezni |
JP2016512815A (ja) | 2013-03-15 | 2016-05-09 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | Atrキナーゼの阻害剤として有用な縮合ピラゾロピリミジン誘導体 |
MX2015014387A (es) | 2013-04-12 | 2017-04-10 | Asana Biosciences Llc | Quinazolinas y azaquinazolinas como inhibidores duales de vias ras/raf/mek/erk y pi3k/akt/pten/mtor. |
RU2687276C2 (ru) | 2013-12-06 | 2019-05-13 | Вертекс Фармасьютикалз Инкорпорейтед | Соединения, пригодные для использования в качестве ингибиторов atr киназы |
JP2017502092A (ja) | 2014-01-14 | 2017-01-19 | ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. | ヘテロアリール及びその使用 |
ES2908042T3 (es) | 2014-01-14 | 2022-04-27 | Takeda Pharmaceuticals Co | Heteroarilos y usos de los mismos |
IN2014DE00554A (es) * | 2014-02-27 | 2015-08-28 | Csir | |
EP3105240B1 (en) | 2014-03-15 | 2018-10-17 | Wake Forest University | Functionalized tyrosine kinase inhibitors modified with precious metal electrophiles and methods associated therewith |
NZ764151A (en) | 2014-06-05 | 2023-12-22 | Vertex Pharma | Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]- pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, the preparation of said compound and different solid forms thereof |
CA2950780C (en) | 2014-06-17 | 2023-05-16 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of chk1 and atr inhibitors |
AU2015362670B2 (en) * | 2014-12-15 | 2019-01-24 | The Regents Of The University Of Michigan | Small molecule inhibitors of EGFR and PI3K |
CN105237484B (zh) * | 2015-09-28 | 2018-12-07 | 西安交通大学 | 一种6-芳基取代的喹啉类化合物及其应用 |
EP3355926A4 (en) | 2015-09-30 | 2019-08-21 | Vertex Pharmaceuticals Inc. | METHOD FOR THE TREATMENT OF CANCER WITH A COMBINATION OF DNA DAMAGING AGENTS AND ATR INHIBITORS |
CN108239074B (zh) * | 2016-12-26 | 2021-07-06 | 中国医学科学院药物研究所 | 喹唑啉类化合物及其制备方法、用途和药物组合物 |
CN108239076B (zh) * | 2016-12-26 | 2021-07-06 | 中国医学科学院药物研究所 | 喹唑啉类化合物及其制备方法、用途和药物组合物 |
EP4169918A1 (en) | 2016-12-26 | 2023-04-26 | Institute of Materia Medica, Chinese Academy of Medical Sciences | Quinazoline compound and preparation method, application, and pharmaceutical compostion thereof |
CN108239075B (zh) * | 2016-12-26 | 2021-07-02 | 中国医学科学院药物研究所 | 喹唑啉类化合物及其制备方法、用途和药物组合物 |
CN108727342A (zh) * | 2017-04-21 | 2018-11-02 | 沈阳药科大学 | 4-芳氨-6-(3-磺酰胺基吡啶)-喹唑啉类衍生物及其制备方法和应用 |
CN108976197A (zh) * | 2017-06-02 | 2018-12-11 | 沈阳药科大学 | 4-烷氨基-喹唑啉类衍生物及其制备方法和应用 |
CN108373462A (zh) * | 2017-12-22 | 2018-08-07 | 西安交通大学 | 6-(吡啶-4-基)-4-取代氨基的喹唑啉或喹啉类化合物及其应用 |
CN112341434B (zh) * | 2019-08-08 | 2021-11-26 | 恩瑞生物医药科技(上海)有限公司 | PI3K/mTOR蛋白降解靶向嵌合体类化合物及其制备方法和医药用途 |
WO2022140456A1 (en) | 2020-12-22 | 2022-06-30 | Mekanistic Therapeutics Llc | Substituted aminobenzyl heteroaryl compounds as egfr and/or pi3k inhibitors |
CN113416181B (zh) * | 2021-08-02 | 2022-05-03 | 四川大学 | 喹唑啉类衍生物及其用途 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9603095D0 (en) * | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
EP0837063A1 (en) * | 1996-10-17 | 1998-04-22 | Pfizer Inc. | 4-Aminoquinazoline derivatives |
GB9800569D0 (en) * | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
US6184226B1 (en) * | 1998-08-28 | 2001-02-06 | Scios Inc. | Quinazoline derivatives as inhibitors of P-38 α |
DK1939203T3 (en) * | 2000-04-25 | 2015-02-23 | Icos Corp | INHIBITORS OF HUMAN phosphatidyl-inositol 3-kinase DELTA ISOFORM |
EP1488809A1 (en) * | 2001-01-16 | 2004-12-22 | Glaxo Group Limited | Pharmaceutical combination containing a 4-quinazolineamine and another anti-neoplastic agent for the treatment of cancer |
EP1353693B1 (en) * | 2001-01-16 | 2005-03-16 | Glaxo Group Limited | Pharmaceutical combination containing a 4-quinazolineamine and paclitaxel, carboplatin or vinorelbine for the treatment of cancer |
DE60227794D1 (de) * | 2001-04-26 | 2008-09-04 | Eisai R&D Man Co Ltd | Stickstoffhaltige verbindung mit kondensiertem ring und pyrazolylgruppe als substituent und medizinische zusammensetzung davon |
EP1528925B1 (en) * | 2002-07-09 | 2009-04-22 | Astrazeneca AB | Quinazoline derivatives for use in the treatment of cancer |
US20070054916A1 (en) * | 2004-10-01 | 2007-03-08 | Amgen Inc. | Aryl nitrogen-containing bicyclic compounds and methods of use |
WO2006071875A1 (en) * | 2004-12-29 | 2006-07-06 | Millennium Pharmaceuticals, Inc. | Compounds useful as chemokine receptor antagonists |
JP5079500B2 (ja) * | 2005-04-28 | 2012-11-21 | 協和発酵キリン株式会社 | 2−アミノキナゾリン誘導体 |
US7989461B2 (en) * | 2005-12-23 | 2011-08-02 | Amgen Inc. | Substituted quinazolinamine compounds for the treatment of cancer |
CN101003514A (zh) * | 2006-01-20 | 2007-07-25 | 上海艾力斯医药科技有限公司 | 喹唑啉衍生物、其制备方法及用途 |
TW200808739A (en) * | 2006-04-06 | 2008-02-16 | Novartis Vaccines & Diagnostic | Quinazolines for PDK1 inhibition |
EP2049502B1 (en) * | 2006-07-28 | 2012-01-04 | Novartis AG | 2,4-substituted quinazolines as lipid kinase inhibitors |
EP2125755A2 (en) * | 2006-12-22 | 2009-12-02 | Novartis Ag | Quinazolines for pdk1 inhibition |
UY31137A1 (es) * | 2007-06-14 | 2009-01-05 | Smithkline Beecham Corp | Derivados de quinazolina como inhibidores de la pi3 quinasa |
EP2211615A4 (en) * | 2007-10-22 | 2010-10-13 | Glaxosmithkline Llc | PYRIDOSULFONAMIDE DERIVATIVES AS PI3 KINASE INHIBITORS |
-
2008
- 2008-06-10 UY UY31137A patent/UY31137A1/es unknown
- 2008-06-12 WO PCT/US2008/066619 patent/WO2008157191A2/en active Application Filing
- 2008-06-12 EP EP08770759A patent/EP2167092A4/en not_active Withdrawn
- 2008-06-12 JP JP2010512333A patent/JP2010532320A/ja active Pending
- 2008-06-12 AR ARP080102512A patent/AR066978A1/es not_active Application Discontinuation
- 2008-06-12 US US12/137,561 patent/US20090018131A1/en not_active Abandoned
- 2008-06-12 US US12/664,496 patent/US20100179144A1/en not_active Abandoned
- 2008-06-12 PE PE2008001006A patent/PE20090835A1/es not_active Application Discontinuation
- 2008-06-12 TW TW097121826A patent/TW200918068A/zh unknown
- 2008-06-12 CL CL2008001743A patent/CL2008001743A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
PE20090835A1 (es) | 2009-07-25 |
US20100179144A1 (en) | 2010-07-15 |
JP2010532320A (ja) | 2010-10-07 |
TW200918068A (en) | 2009-05-01 |
AR066978A1 (es) | 2009-09-23 |
WO2008157191A2 (en) | 2008-12-24 |
WO2008157191A3 (en) | 2011-07-14 |
EP2167092A4 (en) | 2012-07-25 |
CL2008001743A1 (es) | 2009-06-05 |
EP2167092A2 (en) | 2010-03-31 |
US20090018131A1 (en) | 2009-01-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY31137A1 (es) | Derivados de quinazolina como inhibidores de la pi3 quinasa | |
CR11165A (es) | Derivados de quinolina como inhibidores de la p13 quinasa | |
CR10354A (es) | Derivados de tiazolidinadiona como inhibidores de la p13 quinasa | |
DOP2013000059A (es) | Derivados de benzomidazoles como inhibidores de quinasa pi3 | |
DOP2012000227A (es) | Derivados de quinolina como inhibidores de la pi3 quinasa | |
WO2009021083A8 (en) | Quinoxaline derivatives as pi3 kinase inhibitors | |
DOP2022000096A (es) | Formas cristalinas de un inhibidor de tirosina quinasa de bruton | |
ECSP23004573A (es) | Compuestos y composiciones como inhibidores de cinasa de proteina | |
CL2015001160A1 (es) | Compuestos derivados triciclicos fusionados de tiofeno, inhibidores de la cinasa janus (jak); composicion farmaceutica que los comprende; metodo para inhibir la actividad de jak1; metodo para tratar una enfermedad autoinmunitaria, un cancer, un trastorno mieloproliferativo y una enfermedad inflamatoria, entre otras enfermedades. | |
CL2016001055A1 (es) | Compuestos derivados de fenil-aminopirimidina, inhibidores de la tirosina quinasa de bruton (btk), composicion farmaceutica; combinacion farmaceutica; útiles en el tratamiento de enfermedades autoinmunes, inflamatorias, alergicas, de las vias aereas, entre otras. | |
CL2008002006A1 (es) | Compuestos derivados de morfolin pirimidina, composicion farmaceutica, y su uso como inhibidores de la m-tor-quinasa para el tratamiento de l a inflamacion, cancer, enfermedades inmunes, enfermedad obstructiva pulmonar, enfermedad cardiovascular. | |
WO2007103760A3 (en) | Thiazolones for use as pi3 kinase inhibitors | |
CL2008001356A1 (es) | Compuestos derivados de quinoxalina, inhibidores de la pi3 quinasa _(p13ka, pi3ko, pi3b y/o pi3ky); composicion farmaceutica; uso para tratar un trastorno autoinmune, enfermedad inflamatoria, cardiovascular, neurodegerativa, alergia, asma, enfermedad renal, cancer, rechazo de transplante, lesiones pulmonares. | |
ECSP099378A (es) | Compuestos y composiciones como inhibidores de la proteina quinasa | |
DK1802274T3 (da) | Anvendelse af cannabidiol i inhibitionen af hjernetumorcellemigration | |
WO2007136790A3 (en) | Intracellular kinase inhibitors | |
CL2008003096A1 (es) | Compuestos derivados de piperidino-dihidrotienopirimidinas; inhibidores pde4; composicion farmaceutica que los comprende; y uso en el tratamiento de trastornos o enfermedades de las vias respiratorias o gastrointestinales, como tambien enfermedades inflamatorias de las articulaciones u ojos, entre otras. | |
ES2352576T8 (es) | Inhibidores de la replicación del virus de la inmunodeficiencia humana. | |
CL2008001659A1 (es) | Compuestos derivados de quinoxalina como inhibidores de la actividad de cinasa de tirosina de las cinasas janus; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar una enfermedad inmunologica seleccionada a partir de rechazo de trasplante de organo, lupus, esclerosis multiple, entre otras enfermedades. | |
DOP2010000134A (es) | Algunos derivados de 2-pirazinona como inhibidores de elastasa de los neutrofilos | |
CL2007001394A1 (es) | Sistema y metodo computacional para mantener una tabla de entrada de anillo colateral para un modo de un arbol de anillos, los que facilitan la comunicacion de inter-proximidad de una federacion rendezvous. | |
WO2008014219A8 (en) | Thiozolidinedione derivatives as p13 kinase inhibitors | |
ECSP099640A (es) | Compuestos de quinoxalina y uso de los mismos | |
WO2007103754A3 (en) | Thiazolones for use as pi3 kinase inhibitors | |
CL2016000695A1 (es) | Un inhibidor selectivo de la fosfatidilinositol 3-quinasa-gamma |